NASDAQ:PGNX - Progenics Pharmaceuticals Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$7.23 -0.07 (-0.96 %)
(As of 05/21/2018 06:48 AM ET)
Previous Close$7.30
Today's Range$7.12 - $7.31
52-Week Range$4.60 - $8.63
Volume1.57 million shs
Average Volume1.26 million shs
Market Capitalization$532.99 million
P/E RatioN/A
Dividend YieldN/A
Beta2.52

About Progenics Pharmaceuticals (NASDAQ:PGNX)

Progenics Pharmaceuticals logoProgenics Pharmaceuticals, Inc. develops medicines and other technologies to target and treat cancer in the United States and internationally. The company's primary clinical-stage product candidates include Azedra, a radiotherapeutic product candidate, which is in Phase IIb clinical trial under special protocol assessment for the treatment of malignant, recurrent, and/or unresectable pheochromocytoma and paraganglioma; 1404, a technetium-99m labeled small molecule, which is in Phase III clinical trial that acts as an imaging agent to diagnose and detect prostate cancer, as well as soft tissue and bone metastases; and PyL, a fluorinated prostate specific membrane antigen (PSMA)-targeted positron emission topography (PET) imaging agent for prostate cancer. Its clinical-stage product candidates also comprise 1095, a PSMA-targeted Iodine-131 labeled small molecule, which is in Phase I clinical trial for the treatment of metastatic castration-resistant prostate cancer; PSMA TTC, a thorium-227 labeled PSMA-targeted antibody therapeutic that is in pre-clinical stage for treatment of metastatic prostate cancer; and automated bone scan index, a software that quantifies the hotspots on bone scans and calculates the bone scan index value. The company also offers Relistor-subcutaneous injection for the treatment of opioid induced constipation (OIC) in advanced-illness adult patients receiving palliative care when laxative therapy has not been sufficient; and Relistor tablets for the treatment of OIC in adults with chronic non-cancer pain. It has license agreement with Salix Pharmaceuticals, Inc. for the development and commercialization of Relistor worldwide; and with Amgen Fremont, Inc. to use its XenoMouse technology for generating human antibodies to PSMA. Progenics Pharmaceuticals, Inc. was founded in 1986 and is based in New York City, New York.

Receive PGNX News and Ratings via Email

Sign-up to receive the latest news and ratings for PGNX and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
SymbolNASDAQ:PGNX
CUSIP74318710
Phone646-975-2500

Debt

Debt-to-Equity Ratio0.74
Current Ratio6.44
Quick Ratio6.44

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual Sales$11.70 million
Price / Sales45.56
Cash FlowN/A
Price / CashN/A
Book Value$0.90 per share
Price / Book8.03

Profitability

EPS (Most Recent Fiscal Year)($0.90)
Net Income$-51,010,000.00
Net Margins-383.39%
Return on Equity-92.43%
Return on Assets-39.20%

Miscellaneous

Employees64
Outstanding Shares73,720,000

Progenics Pharmaceuticals (NASDAQ:PGNX) Frequently Asked Questions

What is Progenics Pharmaceuticals' stock symbol?

Progenics Pharmaceuticals trades on the NASDAQ under the ticker symbol "PGNX."

How were Progenics Pharmaceuticals' earnings last quarter?

Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX) issued its quarterly earnings results on Wednesday, May, 9th. The biotechnology company reported ($0.19) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.23) by $0.04. The biotechnology company earned $3.19 million during the quarter, compared to the consensus estimate of $4.10 million. Progenics Pharmaceuticals had a negative return on equity of 92.43% and a negative net margin of 383.39%. View Progenics Pharmaceuticals' Earnings History.

When is Progenics Pharmaceuticals' next earnings date?

Progenics Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Wednesday, August, 8th 2018. View Earnings Estimates for Progenics Pharmaceuticals.

What price target have analysts set for PGNX?

4 equities research analysts have issued 1 year target prices for Progenics Pharmaceuticals' shares. Their predictions range from $12.00 to $15.00. On average, they anticipate Progenics Pharmaceuticals' stock price to reach $13.75 in the next twelve months. View Analyst Ratings for Progenics Pharmaceuticals.

What are Wall Street analysts saying about Progenics Pharmaceuticals stock?

Here are some recent quotes from research analysts about Progenics Pharmaceuticals stock:
  • 1. Cantor Fitzgerald analysts commented, ". We maintain an Overweight rating and 12-month PT of $15 on the shares of PGNX. Although we like the rare disease opportunity for AZEDRA (PDUFA 7/30), we also like the PSMA-targeted pipeline for prostate cancer. Moreover, what we have come to appreciate in the PGNX story is the optionality of the pipeline, which extends to the potential for out-licensing, financing and clinical development." (5/20/2018)
  • 2. According to Zacks Investment Research, "Progenics Pharmaceuticals, Inc. is developing innovative medicines for oncology, with a pipeline that includes several product candidates in later-stage clinical development. Progenics' first-in-class PSMA-targeted technology platform for prostate cancer includes an antibody drug conjugate therapeutic in a two-cohort phase 2 clinical trial and a small molecule imaging agent that has completed patient dosing in a phase 2 trial. Among other assets in its pipeline of targeted radiotherapy and molecular imaging compounds is Azedra(TM), an ultra-orphan radiotherapy candidate also in a phase 2 study under an SPA. Progenics' first commercial product, Relistor(R) (methylnaltrexone bromide) for opioid-induced constipation, is partnered with and marketed by Salix Pharmaceuticals, Inc. " (5/11/2018)

Who are some of Progenics Pharmaceuticals' key competitors?

Who are Progenics Pharmaceuticals' key executives?

Progenics Pharmaceuticals' management team includes the folowing people:
  • Mr. Mark R. Baker, CEO & Director (Age 63)
  • Mr. Patrick Fabbio, Sr. VP, CFO & Principal Accounting Officer (Age 50)
  • Dr. Vivien Wong, Exec. VP of Devel. (Age 61)
  • Mr. Jeffrey D. Summer, Sr. VP of Digital Technology (Age 58)
  • Mr. Bryce V. Tenbarge, Sr. VP of Commercial (Age 45)

Has Progenics Pharmaceuticals been receiving favorable news coverage?

News coverage about PGNX stock has trended somewhat positive recently, Accern Sentiment reports. The research firm rates the sentiment of media coverage by monitoring more than twenty million blog and news sources in real-time. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. Progenics Pharmaceuticals earned a news sentiment score of 0.13 on Accern's scale. They also gave news headlines about the biotechnology company an impact score of 47.37 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the company's share price in the near term.

Who are Progenics Pharmaceuticals' major shareholders?

Progenics Pharmaceuticals' stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (13.55%), Eagle Asset Management Inc. (6.06%), Carillon Tower Advisers Inc. (5.36%), Pinnacle Associates Ltd. (2.85%), Schwab Charles Investment Management Inc. (0.49%) and JPMorgan Chase & Co. (0.44%). View Institutional Ownership Trends for Progenics Pharmaceuticals.

Which major investors are selling Progenics Pharmaceuticals stock?

PGNX stock was sold by a variety of institutional investors in the last quarter, including Pinnacle Associates Ltd., Wells Fargo & Company MN, American International Group Inc., BKS Advisors LLC, Teacher Retirement System of Texas and BlackRock Inc.. View Insider Buying and Selling for Progenics Pharmaceuticals.

Which major investors are buying Progenics Pharmaceuticals stock?

PGNX stock was bought by a variety of institutional investors in the last quarter, including Eagle Asset Management Inc., Carillon Tower Advisers Inc., JPMorgan Chase & Co., UBS Group AG, A.R.T. Advisors LLC, Bayesian Capital Management LP, Jane Street Group LLC and Schwab Charles Investment Management Inc.. View Insider Buying and Selling for Progenics Pharmaceuticals.

How do I buy shares of Progenics Pharmaceuticals?

Shares of PGNX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Progenics Pharmaceuticals' stock price today?

One share of PGNX stock can currently be purchased for approximately $7.23.

How big of a company is Progenics Pharmaceuticals?

Progenics Pharmaceuticals has a market capitalization of $532.99 million and generates $11.70 million in revenue each year. The biotechnology company earns $-51,010,000.00 in net income (profit) each year or ($0.90) on an earnings per share basis. Progenics Pharmaceuticals employs 64 workers across the globe.

How can I contact Progenics Pharmaceuticals?

Progenics Pharmaceuticals' mailing address is 285 FULTON STREET 47TH FLOOR, NEW YORK NY, 10007. The biotechnology company can be reached via phone at 646-975-2500 or via email at [email protected]


MarketBeat Community Rating for Progenics Pharmaceuticals (PGNX)

Community Ranking:  2.8 out of 5 (star star)
Outperform Votes:  238 (Vote Outperform)
Underperform Votes:  185 (Vote Underperform)
Total Votes:  423
MarketBeat's community ratings are surveys of what our community members think about Progenics Pharmaceuticals and other stocks. Vote "Outperform" if you believe PGNX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe PGNX will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Progenics Pharmaceuticals (NASDAQ:PGNX) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
4 Wall Street analysts have issued ratings and price targets for Progenics Pharmaceuticals in the last 12 months. Their average twelve-month price target is $13.75, suggesting that the stock has a possible upside of 90.18%. The high price target for PGNX is $15.00 and the low price target for PGNX is $12.00. There are currently 3 buy ratings and 1 strong buy rating for the stock, resulting in a consensus rating of "Buy."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 3.253.253.253.20
Ratings Breakdown: 0 Sell Rating(s)
0 Hold Rating(s)
3 Buy Rating(s)
1 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
3 Buy Rating(s)
1 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
3 Buy Rating(s)
1 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
4 Buy Rating(s)
1 Strong Buy Rating(s)
Consensus Price Target: $13.75$13.75$13.75$13.20
Price Target Upside: 90.18% upside64.47% upside123.58% upside113.25% upside

Progenics Pharmaceuticals (NASDAQ:PGNX) Consensus Price Target History

Price Target History for Progenics Pharmaceuticals (NASDAQ:PGNX)

Progenics Pharmaceuticals (NASDAQ:PGNX) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
5/20/2018Cantor FitzgeraldReiterated RatingBuy$15.00LowView Rating Details
9/1/2017Needham & Company LLCReiterated RatingStrong-Buy$14.00MediumView Rating Details
8/22/2017AegisReiterated RatingBuy$14.00LowView Rating Details
6/8/2017Jefferies GroupReiterated RatingBuy$12.00HighView Rating Details
11/30/2016BTIG ResearchBoost Price TargetBuy$9.00 ➝ $11.00N/AView Rating Details
10/4/2016Brean CapitalInitiated CoverageBuy$11.00N/AView Rating Details
(Data available from 5/21/2016 forward)

Earnings

Progenics Pharmaceuticals (NASDAQ:PGNX) Earnings History and Estimates Chart

Earnings by Quarter for Progenics Pharmaceuticals (NASDAQ:PGNX)

Progenics Pharmaceuticals (NASDAQ:PGNX) Earnings Estimates

2018 EPS Consensus Estimate: ($0.66)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20181($0.23)($0.23)($0.23)
Q2 20181($0.19)($0.19)($0.19)
Q3 20181($0.18)($0.18)($0.18)
Q4 20181($0.06)($0.06)($0.06)

Progenics Pharmaceuticals (NASDAQ PGNX) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
8/7/2018($0.19)N/AView Earnings Details
5/9/2018Q1 2018($0.23)($0.19)$4.10 million$3.19 millionViewN/AView Earnings Details
3/8/2018Q4 2017($0.21)($0.21)$3.18 million$3.90 millionViewN/AView Earnings Details
11/2/2017Q3 2017($0.24)($0.22)$3.58 million$2.70 millionViewN/AView Earnings Details
8/9/2017Q2 2017($0.20)($0.24)$3.34 million$2.77 millionViewListenView Earnings Details
5/4/2017Q1 2017($0.16)($0.23)$4.50 million$2.40 millionViewListenView Earnings Details
3/9/2017Q4 2016($0.20)($0.10)$4.43 million$4.65 millionViewListenView Earnings Details
11/7/2016Q316$0.55$0.52$52.90 million$53.90 millionViewListenView Earnings Details
8/4/2016Q216($0.13)($0.08)$6.33 million$8.50 millionViewN/AView Earnings Details
5/5/2016Q116($0.13)($0.18)$3.27 million$2.50 millionViewListenView Earnings Details
3/11/2016Q415($0.14)($0.10)$2.25 million$5.10 millionViewListenView Earnings Details
11/9/2015Q315($0.13)($0.14)$2.35 million$1.40 millionViewListenView Earnings Details
8/6/2015Q215($0.15)($0.17)$1.63 million$1.90 millionViewListenView Earnings Details
5/6/2015Q115($0.16)($0.15)$1.30 million$0.25 millionViewN/AView Earnings Details
3/16/2015Q414($0.13)($0.18)$2.87 million($0.57) millionViewN/AView Earnings Details
11/7/2014Q314($0.16)$0.51$2.50 million$41.66 millionViewN/AView Earnings Details
8/8/2014Q214($0.14)($0.17)$2.83 million$1.50 millionViewListenView Earnings Details
5/9/2014Q114($0.15)($0.15)$2.88 million$1.80 millionViewN/AView Earnings Details
3/13/2014Q4($0.19)($0.14)$1.48 million$3.00 millionViewListenView Earnings Details
3/3/2014Q4 2013($0.19)($0.14)$1.74 million$2.97 millionViewN/AView Earnings Details
11/11/2013Q313($0.22)($0.17)$2.00 million$0.90 millionViewN/AView Earnings Details
8/9/2013Q2 2013($0.24)($0.24)$1.86 million$1.80 millionViewN/AView Earnings Details
5/10/2013Q1 2013($0.19)($0.22)$1.71 million$2.23 millionViewN/AView Earnings Details
3/15/2013Q4 2012($0.31)($0.01)$1.16 million$8.87 millionViewN/AView Earnings Details
11/8/2012Q312($0.30)($0.33)$2.52 million$1.10 millionViewN/AView Earnings Details
8/9/2012($0.32)($0.32)ViewN/AView Earnings Details
5/8/2012($0.33)($0.39)ViewN/AView Earnings Details
3/15/2012Q4 2011($0.25)($0.32)ViewN/AView Earnings Details
11/9/2011($0.33)($0.34)ViewN/AView Earnings Details
8/9/2011($0.25)$1.64ViewN/AView Earnings Details
5/10/2011($0.51)($0.69)ViewN/AView Earnings Details
3/15/2011($0.57)($0.57)ViewN/AView Earnings Details
11/8/2010Q3 2010($0.56)($0.52)ViewN/AView Earnings Details
8/9/2010Q2 2010($0.54)($0.47)ViewN/AView Earnings Details
5/10/2010Q1 2010($0.41)($0.58)ViewN/AView Earnings Details
3/15/2010Q4 2009($0.14)($0.02)ViewN/AView Earnings Details
11/9/2009Q3 2009($0.44)($0.41)ViewN/AView Earnings Details
8/6/2009Q2 2009($0.50)($0.50)ViewN/AView Earnings Details
5/11/2009Q1 2009($0.27)($0.06)ViewN/AView Earnings Details
3/13/2009Q4 2008($0.30)($0.49)ViewN/AView Earnings Details
11/10/2008Q3 2008($0.28)($0.41)ViewN/AView Earnings Details
8/8/2008Q2 2008$0.01($0.08)ViewN/AView Earnings Details
5/9/2008Q1 2008($0.41)($0.52)ViewN/AView Earnings Details
3/17/2008Q4 2007($0.46)($0.53)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

Progenics Pharmaceuticals (NASDAQ:PGNX) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Progenics Pharmaceuticals (NASDAQ PGNX) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 3.63%
Institutional Ownership Percentage: 86.46%
Insider Trading History for Progenics Pharmaceuticals (NASDAQ:PGNX)
Institutional Ownership by Quarter for Progenics Pharmaceuticals (NASDAQ:PGNX)

Progenics Pharmaceuticals (NASDAQ PGNX) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
2/15/2017Healthcare Master Fun BroadfinMajor ShareholderSell602,600$9.66$5,821,116.00View SEC Filing  
2/9/2017Healthcare Master Fun BroadfinMajor ShareholderSell351,300$9.71$3,411,123.00View SEC Filing  
6/11/2015Robert J IsraelEVPSell2,000$6.83$13,660.00View SEC Filing  
3/13/2015Robert J IsraelEVPSell3,000$7.00$21,000.00View SEC Filing  
3/11/2015Robert J IsraelEVPSell2,000$6.83$13,660.00View SEC Filing  
3/3/2015Robert J IsraelEVPSell5,000$6.49$32,450.00View SEC Filing  
1/12/2015Robert J IsraelEVPSell2,000$7.06$14,120.00View SEC Filing  
12/11/2014Robert J IsraelEVPSell3,000$7.07$21,210.00View SEC Filing  
11/21/2014Robert J IsraelEVPSell9,000$7.00$63,000.00View SEC Filing  
11/13/2014Robert J IsraelEVPSell10,000$6.83$68,300.00View SEC Filing  
11/11/2014Robert J IsraelEVPSell5,000$6.53$32,650.00View SEC Filing  
7/21/2014Healthcare Master Fun BroadfinMajor ShareholderBuy1,625,436$4.60$7,477,005.60View SEC Filing  
7/18/2014Healthcare Master Fun BroadfinMajor ShareholderBuy388,200$4.73$1,836,186.00View SEC Filing  
7/17/2014Healthcare Master Fun BroadfinMajor ShareholderBuy436,884$4.48$1,957,240.32View SEC Filing  
7/16/2014Healthcare Master Fun BroadfinMajor ShareholderBuy411,693$4.48$1,844,384.64View SEC Filing  
7/18/2013Robert J IsraelVPSell5,000$6.33$31,650.00View SEC Filing  
2/27/2013Mark Robert BakerCEOBuy1,262$2.72$3,432.64View SEC Filing  
1/22/2013Mark Robert BakerCEOBuy1,215$2.82$3,426.30View SEC Filing  
12/26/2012Mark Robert BakerCEOBuy1,142$3.01$3,437.42View SEC Filing  
11/28/2012Mark Robert BakerCEOBuy1,607$2.13$3,422.91View SEC Filing  
11/19/2012Mark Robert BakerCEOBuy11,800$1.96$23,128.00View SEC Filing  
11/16/2012Mark Robert BakerCEOBuy49,793$1.82$90,623.26View SEC Filing  
11/15/2012Mark Robert BakerCEOBuy48,833$1.69$82,527.77View SEC Filing  
10/24/2012Mark Robert BakerCEOBuy1,162$2.96$3,439.52View SEC Filing  
9/26/2012Mark Robert BakerCEOBuy1,036$3.32$3,439.52View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Progenics Pharmaceuticals (NASDAQ PGNX) News Headlines

Source:
DateHeadline
Progenics Pharmaceuticals (PGNX) Earns Buy Rating from Cantor FitzgeraldProgenics Pharmaceuticals (PGNX) Earns Buy Rating from Cantor Fitzgerald
www.americanbankingnews.com - May 20 at 9:30 PM
Global Prostate Cancer Therapeutics Strategic Business Report Analysis 2015-2018 Forecast to 2022Global Prostate Cancer Therapeutics Strategic Business Report Analysis 2015-2018 Forecast to 2022
www.prnewswire.com - May 18 at 4:43 PM
Progenics Pharmaceuticals (PGNX) Given Consensus Rating of "Buy" by BrokeragesProgenics Pharmaceuticals (PGNX) Given Consensus Rating of "Buy" by Brokerages
www.americanbankingnews.com - May 14 at 5:58 AM
Q2 2018 EPS Estimates for Progenics Pharmaceuticals (PGNX) Increased by AnalystQ2 2018 EPS Estimates for Progenics Pharmaceuticals (PGNX) Increased by Analyst
www.americanbankingnews.com - May 14 at 1:58 AM
BRIEF-Progenics Pharma, Valeant, Others & Par Sterile Products, Par Pharma Entered Settlement Agreement Relating ...BRIEF-Progenics Pharma, Valeant, Others & Par Sterile Products, Par Pharma Entered Settlement Agreement Relating ...
www.reuters.com - May 13 at 9:37 AM
Progenics Pharmaceuticals (PGNX) Raised to "Hold" at Zacks Investment ResearchProgenics Pharmaceuticals (PGNX) Raised to "Hold" at Zacks Investment Research
www.americanbankingnews.com - May 11 at 12:49 PM
Progenics Pharmaceuticals (PGNX) Forecasted to Post FY2021 Earnings of $0.63 Per ShareProgenics Pharmaceuticals (PGNX) Forecasted to Post FY2021 Earnings of $0.63 Per Share
www.americanbankingnews.com - May 11 at 11:47 AM
Progenics Earnings: Get Ready For A Massive MoveProgenics Earnings: Get Ready For A Massive Move
seekingalpha.com - May 10 at 9:28 AM
Edited Transcript of PGNX earnings conference call or presentation 9-May-18 12:30pm GMTEdited Transcript of PGNX earnings conference call or presentation 9-May-18 12:30pm GMT
finance.yahoo.com - May 10 at 9:28 AM
Progenics Pharmaceuticals Sees Unusually Large Options Volume (PGNX)Progenics Pharmaceuticals Sees Unusually Large Options Volume (PGNX)
www.americanbankingnews.com - May 10 at 7:40 AM
Progenics Pharmaceuticals (PGNX) CEO Mark Baker on Q1 2018 Results - Earnings Call TranscriptProgenics Pharmaceuticals' (PGNX) CEO Mark Baker on Q1 2018 Results - Earnings Call Transcript
seekingalpha.com - May 9 at 4:42 PM
Progenics Pharmaceuticals (PGNX) Given a $15.00 Price Target by Cantor Fitzgerald AnalystsProgenics Pharmaceuticals (PGNX) Given a $15.00 Price Target by Cantor Fitzgerald Analysts
www.americanbankingnews.com - May 9 at 3:17 PM
Progenics Pharmaceuticals (PGNX) Announces Quarterly  Earnings Results, Beats Estimates By $0.04 EPSProgenics Pharmaceuticals (PGNX) Announces Quarterly Earnings Results, Beats Estimates By $0.04 EPS
www.americanbankingnews.com - May 9 at 2:25 PM
Progenics Pharmaceuticals Announces First Quarter 2018 Financial Results and Business UpdateProgenics Pharmaceuticals Announces First Quarter 2018 Financial Results and Business Update
globenewswire.com - May 9 at 9:15 AM
Progenics Pharmaceuticals beats by $0.02, misses on revenueProgenics Pharmaceuticals beats by $0.02, misses on revenue
seekingalpha.com - May 9 at 9:15 AM
Progenics revenues up 39%; net loss improves in Q1Progenics revenues up 39%; net loss improves in Q1
seekingalpha.com - May 9 at 9:15 AM
Progenics Pharmaceuticals Announces First Quarter 2018 Financial Results and Business UpdateProgenics Pharmaceuticals Announces First Quarter 2018 Financial Results and Business Update
finance.yahoo.com - May 9 at 9:15 AM
Progenics: 1Q Earnings SnapshotProgenics: 1Q Earnings Snapshot
finance.yahoo.com - May 9 at 9:15 AM
Noteworthy Tuesday Option Activity: BA, PGNX, AMBANoteworthy Tuesday Option Activity: BA, PGNX, AMBA
www.nasdaq.com - May 8 at 4:43 PM
New Analyst Coverage Puts Spotlight on These 4 StocksNew Analyst Coverage Puts Spotlight on These 4 Stocks
finance.yahoo.com - May 7 at 4:46 PM
Progenics Pharmaceuticals (PGNX) Stock Rating Upgraded by BidaskClubProgenics Pharmaceuticals (PGNX) Stock Rating Upgraded by BidaskClub
www.americanbankingnews.com - May 7 at 11:58 AM
Summary Judgment Granted Upholding the Validity of Formulation Patent Protecting RELISTOR® InjectionSummary Judgment Granted Upholding the Validity of Formulation Patent Protecting RELISTOR® Injection
feeds.benzinga.com - May 2 at 9:45 PM
The No BS Report, Week 11: Rising Tides And Sinking Ships?The No BS Report, Week 11: Rising Tides And Sinking Ships?
seekingalpha.com - May 1 at 9:07 AM
Research Report Identifies Cracker Barrel Old Country Store, Enova International, Natera, Inovalon, UMH Properties ...Research Report Identifies Cracker Barrel Old Country Store, Enova International, Natera, Inovalon, UMH Properties ...
globenewswire.com - May 1 at 9:07 AM
BidaskClub Lowers Progenics Pharmaceuticals (PGNX) to HoldBidaskClub Lowers Progenics Pharmaceuticals (PGNX) to Hold
www.americanbankingnews.com - May 1 at 8:12 AM
Progenics Pharmaceuticals Sets First Quarter 2018 Financial Results Call for May 9Progenics Pharmaceuticals Sets First Quarter 2018 Financial Results Call for May 9
finance.yahoo.com - April 26 at 9:11 AM
Progenics Pharmaceuticals Announces Presentations at the 2018 American Society of Clinical Oncology (ASCO) Annual MeetingProgenics Pharmaceuticals Announces Presentations at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting
finance.yahoo.com - April 26 at 9:11 AM
Progenics Pharmaceuticals (PGNX) to Release Earnings on WednesdayProgenics Pharmaceuticals (PGNX) to Release Earnings on Wednesday
www.americanbankingnews.com - April 25 at 7:33 AM
Progenics Pharmaceuticals (PGNX) Downgraded by BidaskClubProgenics Pharmaceuticals (PGNX) Downgraded by BidaskClub
www.americanbankingnews.com - April 21 at 7:24 AM
Progenics Pharmaceuticals (PGNX) Stock Rating Lowered by BidaskClubProgenics Pharmaceuticals (PGNX) Stock Rating Lowered by BidaskClub
www.americanbankingnews.com - April 19 at 12:49 PM
Progenics Pharmaceuticals, Inc. (PGNX) Receives Consensus Recommendation of "Buy" from BrokeragesProgenics Pharmaceuticals, Inc. (PGNX) Receives Consensus Recommendation of "Buy" from Brokerages
www.americanbankingnews.com - April 19 at 5:56 AM
Cantor Fitzgerald Begins Coverage on Progenics Pharmaceuticals (PGNX)Cantor Fitzgerald Begins Coverage on Progenics Pharmaceuticals (PGNX)
www.americanbankingnews.com - April 18 at 8:34 PM
Progenics Pharmaceuticals (PGNX) PT Set at $15.00 by Cantor FitzgeraldProgenics Pharmaceuticals (PGNX) PT Set at $15.00 by Cantor Fitzgerald
www.americanbankingnews.com - April 11 at 7:19 PM
Progenics Talks Commercialization, Pipeline, And MilestonesProgenics Talks Commercialization, Pipeline, And Milestones
seekingalpha.com - April 10 at 9:29 AM
Progenics Pharmaceuticals (PGNX) Buy Rating Reaffirmed at AegisProgenics Pharmaceuticals' (PGNX) Buy Rating Reaffirmed at Aegis
www.americanbankingnews.com - April 9 at 10:55 PM
Progenics Pharmaceuticals (PGNX) Downgraded by Zacks Investment Research to "Sell"Progenics Pharmaceuticals (PGNX) Downgraded by Zacks Investment Research to "Sell"
www.americanbankingnews.com - April 7 at 7:02 AM
Progenics Pharmaceuticals (PGNX) Downgraded by Zacks Investment ResearchProgenics Pharmaceuticals (PGNX) Downgraded by Zacks Investment Research
www.americanbankingnews.com - April 6 at 6:29 PM
Equities Analysts Set Expectations for Progenics Pharmaceuticals, Inc.s FY2018 Earnings (PGNX)Equities Analysts Set Expectations for Progenics Pharmaceuticals, Inc.'s FY2018 Earnings (PGNX)
www.americanbankingnews.com - April 6 at 7:24 AM
Progenics Pharmaceuticals (PGNX) Downgraded to "Sell" at Zacks Investment ResearchProgenics Pharmaceuticals (PGNX) Downgraded to "Sell" at Zacks Investment Research
www.americanbankingnews.com - April 1 at 11:52 AM
Progenics Pharmaceuticals (PGNX) Given a $15.00 Price Target at Cantor FitzgeraldProgenics Pharmaceuticals (PGNX) Given a $15.00 Price Target at Cantor Fitzgerald
www.americanbankingnews.com - March 31 at 10:54 AM
Progenics Pharmaceuticals (PGNX) Lifted to Buy at Zacks Investment ResearchProgenics Pharmaceuticals (PGNX) Lifted to Buy at Zacks Investment Research
www.americanbankingnews.com - March 30 at 6:15 PM
Progenics Pharmaceuticals (PGNX) Downgraded to "Sell" at ValuEngineProgenics Pharmaceuticals (PGNX) Downgraded to "Sell" at ValuEngine
www.americanbankingnews.com - March 28 at 12:24 PM
Progenics Pharmaceuticals, Inc. (PGNX) Receives Average Rating of "Buy" from BrokeragesProgenics Pharmaceuticals, Inc. (PGNX) Receives Average Rating of "Buy" from Brokerages
www.americanbankingnews.com - March 25 at 5:32 AM
3 Things In Biotech, March 23: Booking 3 Pieces Of Bad News3 Things In Biotech, March 23: Booking 3 Pieces Of Bad News
seekingalpha.com - March 24 at 5:12 PM
Progenics Pharmaceuticals (PGNX) Rating Increased to Buy at BidaskClubProgenics Pharmaceuticals (PGNX) Rating Increased to Buy at BidaskClub
www.americanbankingnews.com - March 24 at 3:52 PM
Is the FDA Expecting More Problems for Progenics? - 24/7 Wall St.Is the FDA Expecting More Problems for Progenics? - 24/7 Wall St.
247wallst.com - March 24 at 8:19 AM
Progenics Pharmaceuticals Inc (NASDAQ:PGNX) Is Expected To BreakevenProgenics Pharmaceuticals Inc (NASDAQ:PGNX) Is Expected To Breakeven
finance.yahoo.com - March 23 at 9:03 AM
Progenics Pharma (PGNX) Announces Three-Month Extension of PDUFA Date for AZEDRA - StreetInsider.comProgenics Pharma (PGNX) Announces Three-Month Extension of PDUFA Date for AZEDRA - StreetInsider.com
www.streetinsider.com - March 22 at 4:53 PM
Progenics Pharmaceuticals Announces Three-Month Extension of PDUFA Date for AZEDRA® (iobenguane I 131) - GlobeNewswire (press release)Progenics Pharmaceuticals Announces Three-Month Extension of PDUFA Date for AZEDRA® (iobenguane I 131) - GlobeNewswire (press release)
globenewswire.com - March 22 at 4:53 PM
Progenics Pharmaceuticals Announces Three-Month Extension of PDUFA Date for AZEDRA® (iobenguane I 131)Progenics Pharmaceuticals Announces Three-Month Extension of PDUFA Date for AZEDRA® (iobenguane I 131)
finance.yahoo.com - March 22 at 4:53 PM

SEC Filings

Progenics Pharmaceuticals (NASDAQ:PGNX) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Progenics Pharmaceuticals (NASDAQ:PGNX) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Progenics Pharmaceuticals (NASDAQ PGNX) Stock Chart for Monday, May, 21, 2018

Loading chart…

This page was last updated on 5/21/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.